mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new...

Descripción completa

Detalles Bibliográficos
Autores principales: BU, CHIWEN, ZHAO, LIGANG, WANG, LISHAN, YU, ZEQIAN, ZHOU, JIAHUA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319595/
https://www.ncbi.nlm.nih.gov/pubmed/37415733
http://dx.doi.org/10.32604/or.2023.029309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319595/
https://www.ncbi.nlm.nih.gov/pubmed/37415733
http://dx.doi.org/10.32604/or.2023.029309

Ejemplares similares